A Phase 1–2 Study of Rovalpituzumab Tesirine in Combination With Nivolumab Plus or Minus Ipilimumab in Patients With Previously Treated Extensive-Stage SCLC
0301 basic medicine
Immunoconjugates
Lung Neoplasms
[SDV.IMM] Life Sciences [q-bio]/Immunology
[SDV.CAN]Life Sciences [q-bio]/Cancer
Antibodies, Monoclonal, Humanized
[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
Antibodies
MESH: Benzodiazepinones
MESH: Ipilimumab
03 medical and health sciences
Clinical trials
[SDV.CAN] Life Sciences [q-bio]/Cancer
Monoclonal
616
Antineoplastic Combined Chemotherapy Protocols
Medicine and Health Sciences
MESH: Immunoconjugates
Humans
Antibody-drug conjugates
Humanized
Benzodiazepinones
MESH: Humans
ICTS (Institute of Clinical and Translational Sciences)
Ipilimumab
MESH: Lung Neoplasms
3. Good health
MESH: Antineoplastic Combined Chemotherapy Protocols
Nivolumab
MESH: Antibodies, Monoclonal, Humanized
MESH: Nivolumab
[SDV.IMM]Life Sciences [q-bio]/Immunology
Small-molecule agents
[SDV.MHEP.PSR] Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tract
Immunotherapy
Lung cancer
DOI:
10.1016/j.jtho.2021.02.022
Publication Date:
2021-02-27T12:25:52Z
AUTHORS (17)
ABSTRACT
AbbVie is committed to responsible data sharing regarding the clinical trials we sponsor.This includes access anonymized, individual and trial-level (analysis sets), as well other information (e.g., protocols Clinical Study Reports), long are not part of an ongoing or planned regulatory submission.This requests for trial unlicensed products indications.These can be requested by any qualified researchers who engage in rigorous, independent scientific research, will provided following review approval a research proposal Statistical Analysis Plan (SAP) execution Data Sharing Agreement (DSA).
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (15)
CITATIONS (52)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....